Arcutis appoints Christopher Peetz to Board of Directors

Arcutis Biotherapeutics, Inc.

Christopher Peetz appointed as Class III director effective July 15, 2026; term expires at 2029 annual meeting.
Peetz is co-founder and CEO of Mirum Pharmaceuticals; brings biopharma leadership and M&A experience.
Received initial option for 21,486 shares; eligible for prorated annual equity (~$350K) and $50K cash retainer.
Board determined Peetz qualifies as independent under SEC and Nasdaq rules; no committee assignment yet.
Appointment expands board from nine to ten members; no family or material transaction relationships disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.